Arrowhead Pharmaceuticals宣布，其药物Redemplo®（Plozasiran）已获得中国国家药品监督管理局（NMPA）的批准，用于治疗家族性乳糜微粒血症综合征（FCS）。这一重要进展标志着该创新疗法在中国市场的正式准入，为FCS患者提供了新的治疗选择。
Arrowhead Pharmaceuticals宣布，其药物Redemplo®（Plozasiran）已获得中国国家药品监督管理局（NMPA）的批准，用于治疗家族性乳糜微粒血症综合征（FCS）。这一重要进展标志着该创新疗法在中国市场的正式准入，为FCS患者提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.